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Abstract The in vitro activity of tigecycline was deter-
mined using a well-defined collection of methicillin-
resistant Staphylococcus aureus (MRSA) isolates (n=202),
including 33 livestock-associated strains. Susceptibility
testing was performed using the Etest system. Among the
202 MRSA strains, three (1.5%) had a minimum inhibitory
concentration (MIC) value for tigecycline greater than
0.5 mg/l, which are considered to be resistant. When these
strains were tested using Iso-Sensitest medium, the MICs
were substantially lower and no resistance was found. This
discrepancy warrants further investigations into the preferred
test conditions for tigecycline. In conclusion, tigecycline
showed good activity against MRSA strains in vitro.
Introduction
Infections caused by methicillin-resistant Staphylococcus
aureus (MRSA) have traditionally been a problem in health-
care settings [1]. According to a report from the National
Nosocomial Infections Surveillance (NNIS) System, ap-
proximately 60% of all S. aureus isolated from patients in
intensive care units in US hospitals were methicillin-
resistant in 2003 [2]. For the last approximately 10 years,
MRSA has expanded its territory to the community, causing
severe infections in previously healthy persons all over the
world [3, 4]. In 2003, a new clone of MRSA was observed
in The Netherlands that is related to an extensive reservoir
in pigs and cattle [5]. The livestock-associated clone is
characterized by being non-typable by SmaI pulsed-field
gel electrophoresis (PFGE). By the end of 2007, nearly
30% of all MRSA observed in The Netherlands were of this
type [6]. There are important differences between livestock-
associated MRSA (LA-MRSA), healthcare-associated
MRSA (HA-MRSA), and community-associated MRSA
(CA-MRSA) regarding the susceptibility against antimicrobi-
al agents. HA-MRSA isolates are frequently multidrug-
resistant, while CA-MRSA and LA-MRSA are relatively
susceptible for most non-beta-lactam antibiotics, with the
exception of tetracycline for LA-MRSA, for which they are
almost always resistant. This is most likely due to the
extensive use of this antimicrobial agent in animal husbandry.
Because tigecycline is related to tetracycline, it is important to
determine the activity of this new drug for LA-MRSA.
The treatment of serious MRSA infections has been
based, for many years, upon the use of glycopeptides, i.e.,
vancomycin and teicoplanin. However, concerns over
increasing rates of heteroresistance and tolerance to
glycopeptides [7] has urged the development of newer
agents. Tigecycline is the first commercially available
E. J. M. Verkade (*) : C. J. M. M. Verhulst :
J. A. J. W. Kluytmans
Laboratory for Microbiology and Infection Control,
Amphia Hospital,
P.O. Box 90158, 4800 RK Breda, The Netherlands
e-mail: everkade@amphia.nl
X. W. Huijsdens
Centre for Infectious Disease,
National Institute for Public Health and the Environment,
Bilthoven, The Netherlands
E. J. M. Verkade
Laboratory for Medical Microbiology and Immunology,
St. Elisabeth Hospital,
Tilburg, The Netherlands
J. A. J. W. Kluytmans
Department of Medical Microbiology,
VU University medical centre,
Amsterdam, The Netherlands
Eur J Clin Microbiol Infect Dis (2010) 29:503–507
DOI 10.1007/s10096-010-0886-2
member of the glycylcyclines, a new class of antimicrobial
agents. The glycylcyclines are derivatives of the tetracy-
cline antibiotics, with structural modifications that result in
activity against gram-positive, gram-negative, and anaero-
bic micro-organisms, including multidrug-resistant strains.
It exhibits generally bacteriostatic action by reversibly
binding to the 30S ribosomal subunit and inhibiting protein
translation [8].
The purpose of the present study was to assess the in vitro
activity of tigecycline against MRSA isolates collected in
The Netherlands using a well-defined collection of strains
that included a representative sample of LA-MRSA strains.
Materials and methods
A total of 202 MRSA isolates were tested in this study. All
MRSA isolates are part of the MRSA strain collection of
the National Institute of Public Health and Environmental
Protection (RIVM), Bilthoven, The Netherlands. The
collection consisted of three subsets. The first set of isolates
used in this study contained 76 MRSA isolates that were
collected between 1990 and 1998 in The Netherlands (old
MRSA). The second set was 93 MRSA isolates collected
between 2003 and 2005 (recent MRSA). These MRSA
strains all had a unique PFGE typing result. The third set of
isolates tested consisted of 33 LA-MRSA strains and were
collected between 2003 and 2005. They had been collected
in a previous study and the strains in our evaluation are the
index cases of the previous survey [9]. All 202 isolates have
been confirmed as S. aureus and methicillin-resistant using
a duplex polymerase chain reaction (PCR) for the mecA
gene and coagulase gene as described previously [10, 11].
The minimum inhibitory concentration (MIC) for tige-
cycline was determined by using the Etest system (AB
Biodisk, Solna, Sweden) with a concentration range of
0.016 to 256 μg/ml. Etest strips contained a concentration
gradient of the antimicrobial agent with a standard amount
of calcium throughout the strip. Etest strips were applied to
the surface of 150–mm Mueller–Hinton agar plates. Plates
were incubated at 35°C in ambient air for 24 h prior to
reading the MIC results. In addition, the MICs of the
following antimicrobial agents were determined simulta-
neously: oxacillin, gentamicin, cotrimoxazole, ciprofloxa-
cin, erythromycin, clindamycin, rifampin, daptomycin,
tetracycline, linezolid, vancomycin, and teicoplanin. All
MICs were determined using the Etest system. For
vancomycin and teicoplanin, the Etest strips were placed
on brain heart infusion agar, using a high inoculum (2.0
McFarland) and an extended incubation time (48 h) to be
able to detect hGISA isolates. Isolates were categorized as
susceptible or resistant to an antimicrobial agent according
to the breakpoints published by the Clinical and Laboratory
Standards Institute (CLSI) [12]. The proposed breakpoint
for tigecycline is greater than 0.5 mg/l for S. aureus (both
methicillin-resistant and methicillin-susceptible strains).
The 11 MRSA strains with the highest MIC for tigecycline
on Mueller–Hinton agar plates were subsequently applied
on 90-mm Iso-Sensitest agar plates (Oxoid Ltd.). The plates
were then incubated at 35°C in ambient air for 24 h prior to
reading the MIC results.
All results were entered into a database and further
statistical analyses were performed using SPSS software.
The MIC values for all tested antimicrobial agents of the
different subsets of strains were compared using the Mann–
Whitney U-test.
Results and discussion
The observed MIC range for tigecycline was 0.05 to
1.0 μg/ml, with MIC values at which 50 and 90% of the
isolates tested are inhibited (MIC50 and MIC90) of 0.19 and
0.38 μg/ml, respectively. The MIC50 and MIC90 of LA-
MRSA, old MRSA, and recent MRSA isolates for
tigecycline and other antibiotics are outlined in Table 1.
No significant difference was found in the portion of
tigecycline resistance between recent MRSA and old MRSA.
None of the LA-MRSA isolates were resistant for tigecycline.
Three (2%) of the 169 testedMRSA isolates were resistant for
tigecycline. Of the 76 old MRSA isolates, two (3%) isolates
had MICs for tigecycline greater than 0.5 μg/ml and are,
therefore, considered to be resistant for tigecycline. In
addition, one isolate (1%) of the 93 recent MRSA strains
had an MIC value for tigecycline greater than 0.5 μg/ml. The
11 MRSA strains with the highest MIC for tigecycline on
Mueller–Hinton agar plates were retested using Etest strips
that were applied on Iso-Sensitest agar plates (Oxoid Ltd.) and
simultaneously on Mueller–Hinton agar plates. The MIC
values for tigecycline of the 11 MRSA strains applied on
Mueller–Hinton agar plates were comparable with the
previously obtained MIC values. On Iso-Sensitest medium,
these 11 MRSA strains had significantly 2-fold lower MIC
values for tigecycline using linear regression analysis (p<
0.001). Figure 1 shows the shift towards lower MIC values
for tigecycline when MRSA strains were applied on Iso-
Sensitest medium. The MICs for tigecycline showed a
significant correlation with those of tetracycline (r=0.518;
p<0.001) and teicoplanin (r=0.325; p<0.001).
LA-MRSA was the most susceptible group of strains.
They were only significantly more often resistant to
tetracycline (Table 1). Old MRSA strains were more often
resistant to most groups of antimicrobial agents, compared
to recent MRSA. The only agent that was significantly (p<
0.001) more resistant in recent strains in comparison with
old strains was vancomycin.
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In a well-defined collection of MRSA, we found that a
minority (1.5%) was resistant for tigecycline. All strains were
isolated before tigecycline had been used in patients. The
results of this study slightly differed from other data on
European and North American antibiotic-resistant clinical
isolates that were phenotypically characterized [13–15]. In a
recent study, the in vitro activity of tigecycline against 38
MRSA and the correlation of this activity with their resistance
gene content were determined [16]. Tigecycline demonstrated
good activity against MRSA, with MIC50 and MIC90 values
of 0.12 and 0.25 μg/ml, respectively. Overall, tigecycline
showed an MIC range of 0.06 to 0.25 μg/ml. The tigecycline
MICs determined in our study were slightly higher.
In another study, Fluit et al. [17] found the MIC range for
tigecycline to be 0.06 to 2.0 μg/ml. For the 106 S. aureus
isolates tested, two (2%) isolates had MIC values for
tigecycline greater than 0.5 μg/ml and are, therefore,
considered to be resistant. These findings are identical to our
results. In our study, the MICs for tigecycline showed a
significant correlation with the MICs for tetracycline. Fluit et
al. found no relation between the presence of tetracycline
resistance determinants tet(K) or tet(M) and the MICs for
tigecycline observed for S. aureus, although tetracycline-
susceptible isolates were more often susceptible to tigecycline.
The possible correlation of the in vitro susceptibility of
tigecycline and tetracycline prompted us to include LA-
MRSA in the evaluation. These strains are known to have
high levels of tetracycline resistance. Also, the current
evaluation showed that 28 out of the 33 (85%) LA-MRSA
strains were resistant against tetracycline. However, none of
the LA-MRSA isolates tested was resistant against tigecy-
cline. Conversely, we found tigecycline resistance in three
of the HA-MRSA strains when incubated on Mueller–
Hinton agar plates. Because of the recently reported
influence of the test conditions on the in vitro susceptibility
of tigecycline, we also tested a subset of the strains on Iso-
Sensitest medium [18]. Eleven MRSA strains with the
highest MICs for tigecycline were selected and retested on
Mueller–Hinton agar and on Iso-Sensitest medium. On
Mueller–Hinton agar, the results were identical to the initial
MIC on Mueller-Hinton
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Fig. 1 Linear regression analysis of MIC values for tigecycline using
Mueller–Hinton medium and Iso-Sensitest medium
Table 1 MIC50 and MIC90 values of antimicrobial agents against 76 MRSA collected between 1990 and 1998 (old MRSA), 93 MRSA collected
between 2003 and 2005 (recent MRSA), and 33 livestock-associated MRSA (LA-MRSA) strains collected in The Netherlands between 2003 and 2005
Antibiotic Old MRSA Recent MRSA LA-MRSA p-value
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 Old vs. recent Old vs. LA Recent vs. LA
Tigecycline 0.19 0.42 0.19 0.38 0.25 0.38 0.618 0.230 0.296
Oxacillin 256 256 32.0 256 12.0 48.0 <0.001a <0.001a <0.001a
Gentamicin 12 256 0.75 41.6 0.38 9.9 <0.001a <0.001a <0.001a
Cotrimoxazole 0.13 32 0.025 0.525 0.02 0.13 <0.001a <0.001a 0.202
Ciprofloxacin 32 32 24.0 32.0 0.38 1.8 <0.001a <0.001a <0.001a
Erythromycin 256 256 0.38 256 0.25 256 <0.001a <0.001a 0.036
Clindamycin 0.19 256 0.09 256 0.06 256 <0.001a <0.001a 0.179
Rifampin 0.012 32 0.006 0.60 0.004 0.006 <0.001a <0.001a <0.001a
Daptomycin 0.38 0.75 0.38 0.75 0.13 0.19 0.243 <0.001a <0.001a
Tetracycline 12 32 0.38 29.6 32 48 0.001a <0.001a <0.001a
Linezolid 1.0 1.5 1.0 1.5 0.75 1.0 0.032 <0.001a <0.001a
Vancomycinb 3.0 4.0 4.0 8.0 4.0 4.0 <0.001a 0.176 0.077
Teicoplaninb 3.5 12 4.0 12.0 3.0 4.0 0.385 0.05 <0.001a
a A p-value of <0.01 is considered to be statistically significant
b The Etest system with a high inoculum and 48 h of incubation was used
Eur J Clin Microbiol Infect Dis (2010) 29:503–507 505
result, but on Iso-Sensitest medium, the MICs for tigecy-
cline were much lower, and all strains were considered to
be susceptible. The results for tigecycline are influenced by
the concentration of manganese in the medium [18]. As
Mueller–Hinton agar is a biological medium, the concen-
tration of manganese may vary. Iso-Sensitest is a biochem-
ical medium, which is well-defined. However, the CLSI
standard recommends the use of Mueller–Hinton medium
for the susceptibility testing of tigecycline using the Etest
system [19]. This discrepancy requires further investiga-
tions into the underlying mechanisms.
An interesting aspect of this study is the remarkable
difference in resistance against various classes of antibiotics
between old and more recent strains of MRSA. The older strains
were, in general, much more resistant than the more recent
strains (Table 1). This may reflect the emergence of CA-MRSA
in recent years, which are, in general, more susceptible [4]. The
only antimicrobial agent with significantly higher MICs in
recent MRSAwas vancomycin. This has recently been reported
by other groups and may reflect the increased use of this agent
in hospitals all over the world [20, 21]. As vancomycin is
considered to be the cornerstone of therapy for serious MRSA
infections, the increasing MICs are a worrying finding. It
stresses the need for alternative therapeutic agents. The LA-
MRSA strains were also relatively susceptible to many classes
of antibiotics, with the exception of tetracycline. MICs for
tigecycline were comparable in all three groups of strains.
In conclusion, tigecycline exhibited broad in vitro activity
against a collection of MRSA strains collected in The
Netherlands, including livestock-associated strains. Using
the recommended methodology, we found three strains to be
resistant. However, these strains were considered to be
susceptible when Iso-Sensitest medium was used. This
discrepancy warrants further investigations into the preferred
test conditions because the interpretation of the in vitro
susceptibility of tigecycline is affected significantly.
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